(Q48248436)

9 February 2018

title

Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. (English)

1 reference

9 February 2018

pancreatic adenocarcinoma

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28803454%20AND%20SRC:MED&resulttype=core&format=json

Vijayaragavan Muralidharan

9 June 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28803454%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Grace Gold

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28803454%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Christopher Christophi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28803454%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Christopher Christophi

3

object named as

Christopher Christophi

1 reference

9 February 2018

author name string

Grace Gold

2

1 reference

9 February 2018

publication date

13 August 2017

1 reference

9 February 2018

published in

ANZ Journal of Surgery

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28803454%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28803454%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28803454%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

987-992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28803454%20AND%20SRC:MED&resulttype=core&format=json

Colorectal carcinoma antigens detected by hybridoma antibodies

9 June 2020

cites work

1 reference

Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies

21 January 2018

1 reference

The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays

21 January 2018

1 reference

Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases

21 January 2018

1 reference

Lipid rafts and signal transduction

21 January 2018

1 reference

Disialoganglioside GD3 is released by microglia and induces oligodendrocyte apoptosis

21 January 2018

1 reference

Complex gangliosides are essential in spermatogenesis of mice: possible roles in the transport of testosterone

21 January 2018

1 reference

Mucins in cancer: protection and control of the cell surface

21 January 2018

1 reference

Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen

21 January 2018

1 reference

Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer

21 January 2018

1 reference

Consequences of the expression of sialylated antigens in breast cancer

21 January 2018

1 reference

Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population

21 January 2018

1 reference

Pancreatic adenocarcinoma

21 January 2018

1 reference

Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study

21 January 2018

1 reference

Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

21 January 2018

1 reference

Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis

21 January 2018

1 reference

The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma

21 January 2018

1 reference

Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA

21 January 2018

1 reference

Serum biomarker panels for the detection of pancreatic cancer

21 January 2018

1 reference

High CA 19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature

21 January 2018

1 reference

CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions

21 January 2018

1 reference

Hepatobiliary cystadenomas and cystadenocarcinomas: a report of 33 cases

21 January 2018

1 reference

Clinical factors predictive of malignant and premalignant cystic neoplasms of the pancreas: a single institution experience

21 January 2018

1 reference

Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma

21 January 2018

1 reference

CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy

21 January 2018

1 reference

High serum CA 19-9 but not tumor size should select patients for staging laparoscopy in radiological resectable pancreas head and peri-ampullary cancer

21 January 2018

1 reference

Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy

21 January 2018

1 reference

Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma

21 January 2018

1 reference

Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704

21 January 2018

1 reference

Pancreatic cancer surgery in the new millennium: better prediction of outcome

21 January 2018

1 reference

The prognostic and predictive value of serum CA19.9 in pancreatic cancer

21 January 2018

1 reference

Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution

21 January 2018

1 reference

Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease.

21 January 2018

1 reference

Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine

21 January 2018

1 reference

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

21 January 2018

1 reference

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

21 January 2018

1 reference

Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer

21 January 2018

1 reference

CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy

21 January 2018

1 reference

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

21 January 2018

1 reference

Extremely elevated CA19-9 in acute cholangitis.

21 January 2018

1 reference

Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

Post-Whipple imaging in patients with pancreatic ductal adenocarcinoma: association with overall survival: a multivariate analysis

21 January 2018

1 reference

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ANS.14131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28803454%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference